Recent Updates
Recently added Catalysts
TLX Negative Sentiment Score: 25/100

Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights – TLX

Key Takeaway: Telix Pharmaceuticals Ltd. is facing a class action securities lawsuit initiated by Levi & Korsinsky LLP, focusing on allegations of securities fraud. The lawsuit centers on claims that the company made false statements regarding its progress in developing prostate cancer therapeutics and misrepresented the quality of its supply chain and partners. Investors who suffered losses from February 21, 2025, to August 28, 2025, have until January 9, 2026, to seek the appointment as lead plaintiff. The lawsuit offers participation without any out-of-pocket costs for class members.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Telix Pharmaceuticals over alleged securities fraud.
  • Investors claim that the company overstated progress on prostate cancer therapies.
  • Allegations include misleading statements about supply chain quality.

Full Press Release Details

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:
TLX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT'S NEXT? If you suffered a loss in Telix Pharmaceuticals Ltd. during the relevant time frame, you have until January 9, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the main issue in the Telix Pharmaceuticals lawsuit?

The lawsuit claims that Telix Pharmaceuticals made false statements regarding its business and operations.

Who can participate in the Telix Pharmaceuticals class action?

Investors who experienced losses from February 21, 2025, to August 28, 2025, can participate.

What are the costs associated with participating in the lawsuit?

Class members may participate without any out-of-pocket costs or fees.

When is the deadline to request lead plaintiff status?

The deadline to request lead plaintiff status is January 9, 2026.

How can investors contact Levi & Korsinsky for more information?

Investors can email jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: Dec 26, 2025